42 Genetics

42 Genetics is a UK-based genetic testing and AI-driven drug discovery startup that emerged in the mid-2020s amid growing interest in precision medicine.

Reviewed by 7wData
Share Email

On this page

Profile

Develops AI-powered genetic analysis tools for drug discovery and personalized medicine.

42 Genetics is a UK-based genetic testing and AI-driven drug discovery startup that emerged in the mid-2020s amid growing interest in precision medicine. While foundational details about its founding team and funding remain undisclosed in public records, the company operates at the intersection of healthcare AI and genomic analysis, focusing on scalable data-driven solutions for patient care. Its technology appears aligned with broader industry trends toward using genetic data for personalized treatment optimization, though it lacks the public controversies seen in competitors like Nucleus Genomics, which raised $14M in Series A funding in early 2025.

The company's website suggests involvement in drug safety case studies and patient-centered research, but concrete revenue figures or headcount are not publicly available. Recent industry shifts, such as Eli Lilly's $19.3B Q4 2025 revenue driven by GLP-1 drugs and Bayer's focus on genetic treatment technologies, indicate a competitive landscape for genetic data applications. 42 Genetics has not disclosed partnerships with major pharmaceutical firms, unlike peers engaged in high-profile collaborations.

Track 42 Genetics and 240+ vendors.

335k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Pharmaceutical companies seeking drug development insights
  • Healthcare providers implementing precision medicine programs
  • Research institutions studying genetic markers
  • Biotech startups requiring genomic data analysis

Strengths and what to watch

Strengths

  • Operates in high-growth sector combining AI and genomics, projected to expand significantly through 2032
  • UK base provides access to National Health Service data partnerships
  • Avoided public controversies plaguing some genetic testing competitors

Watch for

  • Lack of disclosed funding rounds compared to rivals like Nucleus Genomics
  • Dependence on unproven AI models for clinical interpretations
  • Regulatory scrutiny increasing for genetic data handling in healthcare

Key Information

Founded
2011
Headquarters
Belfast

Frequently Asked Questions

What does 42 Genetics do?

42 Genetics develops AI-powered genetic analysis tools for drug discovery and personalized medicine. The UK-based startup focuses on scalable, data-driven solutions for healthcare, leveraging genomic data to optimize patient care and advance precision medicine applications.

How does 42 Genetics use AI in genetic analysis?

42 Genetics uses AI to analyze genomic data, enabling insights for drug discovery and personalized medicine. Their technology supports scalable solutions for healthcare providers and researchers, helping optimize treatments and identify genetic markers for improved patient outcomes.

Who are the main customers of 42 Genetics?

42 Genetics serves pharmaceutical companies, healthcare providers, research institutions, and biotech startups. Their tools support drug development, precision medicine programs, genetic marker studies, and genomic data analysis, catering to diverse needs in the healthcare and biotech sectors.

How does 42 Genetics compare to other genetic testing startups?

42 Genetics operates in the competitive genetic testing sector, focusing on AI-driven drug discovery and precision medicine. Unlike some rivals, it has avoided public controversies but lacks disclosed funding rounds or high-profile pharmaceutical partnerships seen with competitors like Nucleus Genomics.

What are the strengths of 42 Genetics?

42 Genetics benefits from operating in the high-growth AI and genomics sector, with access to UK National Health Service data partnerships. It avoids public controversies and focuses on scalable, data-driven solutions for drug discovery and precision medicine.

What challenges does 42 Genetics face?

42 Genetics faces challenges like undisclosed funding compared to rivals, reliance on unproven AI models for clinical interpretations, and increasing regulatory scrutiny over genetic data handling. These factors could impact its growth and adoption in the competitive healthcare AI landscape.

Sources

  1. techcrunch.com — Competitive funding landscape for genetic testing startups
  2. www.prnewswire.com — Pharmaceutical industry revenue context for genetic applications
  3. www.reuters.com — Industry investment in genetic treatment technologies
  4. www.linkedin.com — Company's focus on AI-driven drug discovery applications